Clinical trial
Docetaxel With or Without PI-88 in Treating Patients With Stage IIIB or Stage IV…
NCT00103389 · Cellxpert Biotechnology Corp., Industry · Completed
Key facts
| NCT number | NCT00103389 |
|---|---|
| Title | Docetaxel With or Without PI-88 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer |
| Official title | A Phase II Study of Docetaxel With PI-88 in Patients With Advanced Non-Small-Cell Lung Cancer |
| Lead sponsor | Cellxpert Biotechnology Corp., Industry |
| Collaborators | Medigen Biotechnology Corporation Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | PI-88, docetaxel |
| Enrollment | 98 |
| Start date | Feb 1, 2004 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Feb 8, 2005 |
| Last update posted | Jun 27, 2022 |
| Countries | Australia |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: